Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 2/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2170360 | 0.82 | CA12 (0.42) | MAOBL3MBTL1ALDH1A1MAPTMEN1 | |
| SCHEMBL22527540 | 0.80 | CA12 (0.49) | MAOBAOC3EPHX2MRGPRX4L3MBTL1 | |
| SCHEMBL10707563 | 0.80 | ACACB (0.39) | ALDH1A1ACACBKIF11SMN1; SMN2 | |
| SCHEMBL513003 | 0.80 | ALDH1A1 (0.49) | MAOBAOC3MRGPRX4ALDH1A1KIF11 | |
| SCHEMBL97113 | 0.77 | EPHX2 (0.47) | MAOBAOC3EPHX2MRGPRX4L3MBTL1 | |
| SCHEMBL2095929 | 0.77 | MAOB (0.47) | MAOBAOC3EPHX2MRGPRX4L3MBTL1 | |
| SCHEMBL99544 | 0.77 | DAO (0.43) | MAOBL3MBTL1CYP1A2CYP2C19NPC1 | |
| SCHEMBL3941478 | 0.76 | SLC6A4 (0.45) | EPHX2ALDH1A1MAPTACACBGPR84 | |
| SCHEMBL254957 | 0.75 | MAPT (0.56) | MAOBAOC3EPHX2L3MBTL1ALDH1A1 | |
| SCHEMBL2089953 | 0.73 | MAOB (0.45) | MAOBAOC3EPHX2MRGPRX4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6107284-A | Water-soluble derivatives of epipodophyllotoxin, process for their preparation, their use as medicinal products and their intended use in anti-cancer treatments | PIERRE FABRE MEDICAMENT (FR) | 2000-08-22 | — | — | US | claimed |
| EP-0787135-B1 | WATER-SOLUBLE EPIPODOPHYLLOTOXIN DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF AS A DRUG AND FOR TREATING CANCER | PF MEDICAMENT (FR) | 2000-05-24 | — | — | EP | claimed |
| EP-0787135-A1 | WATER-SOLUBLE EPIPODOPHYLLOTOXIN DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF AS A DRUG AND FOR TREATING CANCER | PIERRE FABRE MEDICAMENT (FR) | 1997-08-06 | — | — | EP | claimed |
| EP-0675895-B1 | ETOPOSIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A DRUG AND IN THE PREPARATION OF A DRUG FOR TREATING CANCER | PF MEDICAMENT (FR) | 1997-07-23 | — | — | EP | claimed |
| US-5643885-A | Etoposide derivatives, process for preparing them, their use as a medicinal product and their use for the preparation of a medicinal product intended for anti-cancer treatment | PIERRE FABRE MEDICAMENT (FR) | 1997-07-01 | — | — | US | claimed |
| JP-H08504795-A | — | — | 1996-05-21 | — | — | JP | claimed |
| WO-1996012727-A1 | WATER-SOLUBLE EPIPODOPHYLLOTOXIN DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF AS A DRUG AND FOR TREATING CANCER | PIERRE FABRE MEDICAMENT (FR) | 1996-05-02 | — | — | WO | claimed |
| WO-2024129931-A1 | ALPHA-V BETA-6(ανβ6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2023210623-A1 | HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME | 株式会社エス・ディー・エス バイオテック | 2023-11-02 | — | — | WO | disclosed |
| WO-2014184071-A1 | MIXTURES OF HALOALKYLSULFONANILIDE DERIVATIVES AND HERBICIDES | SYNGENTA LIMITED (GB) | 2014-11-20 | — | — | WO | disclosed |
| WO-2014184070-A1 | MIXTURES OF HALOALKYLSULFONANILIDE DERIVATIVES AND HERBICIDES | SYNGENTA LIMITED (GB) | 2014-11-20 | — | — | WO | disclosed |
| EP-2420493-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | Nissan Chemical Industries, Ltd. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120029187-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2336104-A1 | ORTHO-SUBSTITUTED HALOALKYLSULFONANILIDE DERIVATIVE AND HERBICIDE | Nissan Chemical Industries, Ltd. (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-6107284-A | Water-soluble derivatives of epipodophyllotoxin, process for their preparation, their use as medicinal products and their intended use in anti-cancer treatments | PIERRE FABRE MEDICAMENT (FR) | 2000-08-22 | — | — | US | disclosed |
| EP-0787135-B1 | WATER-SOLUBLE EPIPODOPHYLLOTOXIN DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF AS A DRUG AND FOR TREATING CANCER | PF MEDICAMENT (FR) | 2000-05-24 | — | — | EP | disclosed |
| EP-0787135-A1 | WATER-SOLUBLE EPIPODOPHYLLOTOXIN DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF AS A DRUG AND FOR TREATING CANCER | PIERRE FABRE MEDICAMENT (FR) | 1997-08-06 | — | — | EP | disclosed |
| EP-0675895-B1 | ETOPOSIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A DRUG AND IN THE PREPARATION OF A DRUG FOR TREATING CANCER | PF MEDICAMENT (FR) | 1997-07-23 | — | — | EP | disclosed |
| US-5643885-A | Etoposide derivatives, process for preparing them, their use as a medicinal product and their use for the preparation of a medicinal product intended for anti-cancer treatment | PIERRE FABRE MEDICAMENT (FR) | 1997-07-01 | — | — | US | disclosed |
| WO-1996012727-A1 | WATER-SOLUBLE EPIPODOPHYLLOTOXIN DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF AS A DRUG AND FOR TREATING CANCER | PIERRE FABRE MEDICAMENT (FR) | 1996-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029187-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | CBR3, CBR1, HDHD5 | MAOB 3755/4885AOC3 894/4885EPHX2 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.